                         SEQUENCE LISTING

<110>  THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE 
       SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
 
<120>  NATIVE AND AGONIST CTL EPITOPES OF THE MUC1 TUMOR ANTIGEN

<130>  711788

<150>  US 61/582,723
<151>  2012-01-03

<160>  32    

<170>  PatentIn version 3.5

<210>  1
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  1

Ala Leu Ala Ile Val Tyr Leu Ile Ala Leu 
1               5                   10  


<210>  2
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  2

Tyr Leu Ala Ile Val Tyr Leu Ile Ala Leu 
1               5                   10  


<210>  3
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  wherein Xaa is Ala or Tyr

<400>  3

Xaa Leu Ala Ile Val Tyr Leu Ile Ala Leu 
1               5                   10  


<210>  4
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  4

Tyr Leu Ile Ala Leu Ala Val Cys Gln Cys 
1               5                   10  


<210>  5
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  5

Tyr Leu Ile Ala Leu Ala Val Cys Gln Val 
1               5                   10  


<210>  6
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  wherein Xaa is Cys or Val

<400>  6

Tyr Leu Ile Ala Leu Ala Val Cys Gln Xaa 
1               5                   10  


<210>  7
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  7

Ser Leu Ser Tyr Thr Asn Pro Ala Val 
1               5                   


<210>  8
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  8

Tyr Leu Ser Tyr Thr Asn Pro Ala Val 
1               5                   


<210>  9
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  wherein Xaa is Ser or Tyr

<400>  9

Xaa Leu Ser Tyr Thr Asn Pro Ala Val 
1               5                   


<210>  10
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  10

Ala Leu Phe Ile Val Tyr Leu Ile Ala Lys 
1               5                   10  


<210>  11
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  wherein Xaa is Ala or Phe

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  wherein Xaa is Leu or Lys

<400>  11

Ala Leu Xaa Ile Val Tyr Leu Ile Ala Xaa 
1               5                   10  


<210>  12
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  12

Ser Thr Asp Arg Ser Pro Tyr Glu Lys 
1               5                   


<210>  13
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  13

Ser Leu Tyr Arg Ser Pro Tyr Glu Lys 
1               5                   


<210>  14
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  14

Ser Leu Phe Arg Ser Pro Tyr Glu Lys 
1               5                   


<210>  15
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  wherein Xaa is Thr or Leu

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  wherein Xaa is Asp, Tyr, or Phe

<400>  15

Ser Xaa Xaa Arg Ser Pro Tyr Glu Lys 
1               5                   


<210>  16
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  16

Gly Leu Phe Asp Glu Tyr Leu Glu Met Val 
1               5                   10  


<210>  17
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  17

His Leu Phe Gly Tyr Ser Trp Tyr Lys 
1               5                   


<210>  18
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  18

Leu Leu Val Leu Val Cys Val Leu Val Ala 
1               5                   10  


<210>  19
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  19

Leu Leu Val Leu Val Ile Val Leu Val Lys 
1               5                   10  


<210>  20
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  20

Leu Leu Val Leu Val Cys Val Leu Val Lys 
1               5                   10  


<210>  21
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  21

Gly Gln Leu Asp Ile Phe Pro Ala Arg 
1               5                   


<210>  22
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  22

Gly Leu Leu Asp Ile Phe Pro Ala Lys 
1               5                   


<210>  23
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  23

Gly Gln Leu Asp Ile Phe Pro Ala Arg 
1               5                   


<210>  24
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  24

Gly Leu Leu Asp Ile Phe Pro Ala Lys 
1               5                   


<210>  25
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  25

Ser Leu Tyr Asn Thr Val Ala Thr Leu 
1               5                   


<210>  26
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  wherein Xaa is Ser or Tyr

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  wherein Xaa is Thr or Leu

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  wherein Xaa is Asn or Gly

<400>  26

Xaa Xaa Ala Pro Pro Ala His Xaa Val 
1               5                   


<210>  27
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  27

Ser Thr Ala Pro Pro Ala His Asn Val 
1               5                   


<210>  28
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  28

Ser Thr Ala Pro Pro Ala His Gly Val 
1               5                   


<210>  29
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  29

Tyr Leu Ala Pro Pro Ala His Gly Val 
1               5                   


<210>  30
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  wherein Xaa is Ala or Tyr

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  wherein Xaa is Pro or Leu

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  wherein Xaa is Gly or Val

<400>  30

Xaa Xaa Asp Thr Arg Pro Ala Pro Xaa 
1               5                   


<210>  31
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  31

Ala Pro Asp Thr Arg Pro Ala Pro Gly 
1               5                   


<210>  32
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  32

Tyr Leu Asp Thr Arg Pro Ala Pro Val 
1               5                   


